$MD
Pediatrix Medical Group, Inc. Stock $md

$md Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000095017023003127 Filed on February 17, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$491.0M	$513.8M	$1.972B
YoY Change	1.82%	3.07%	3.18%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$421.3M	$417.6M	$1.615B
YoY Change	4.17%	6.63%	3.45%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$8.953M	$9.136M	$35.64M
YoY Change	2.1%	16.25%	10.85%
% of Gross Profit
Operating Expenses	$461.0M	$458.2M	$1.799B
YoY Change	4.03%	7.2%	5.33%
Operating Profit	$30.04M		$172.7M
YoY Change	-23.18%		-14.9%
Interest Expense	$10.39M	-$8.214M	$39.70M
YoY Change	-12.08%	-43.31%	-42.24%
% of Operating Profit	34.59%		22.99%
Other Income/Expense, Net	-$9.329M		-$91.32M
YoY Change	-86.17%		34.91%
Pretax Income	$20.71M	$27.82M	$81.37M
YoY Change	-173.07%	-48.01%	-39.83%
Income Tax	$6.506M	$3.824M	$18.81M
% Of Pretax Income	31.41%	13.74%	23.11%
Net Earnings	$14.21M	$29.66M	$66.34M
YoY Change	-167.05%	-37.58%	-49.35%
Net Earnings / Revenue	2.89%	5.77%	3.36%
Basic Earnings Per Share	$0.17		$0.79
Diluted Earnings Per Share	$0.17	$0.36	$0.79
COMMON SHARES
Basic Shares Outstanding	83.03M	83.07M	83.47M
Diluted Shares Outstanding	82.32M		84.12M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$102.8M	$103.1M	$103.1M
YoY Change	6.28%	-78.84%	-78.84%
Cash & Equivalents	$6.124M	$9.824M	$9.824M
Short-Term Investments	$96.71M	$93.24M	$93.24M
Other Short-Term Assets	$12.07M	$13.26M	$28.14M
YoY Change	32.92%	-29.82%	-24.83%
Inventory
Prepaid Expenses	$14.95M	$14.88M
Receivables	$278.7M	$296.8M	$296.8M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$408.6M	$428.0M	$428.0M
YoY Change	-7.09%	-49.08%	-49.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$72.93M	$73.29M	$140.2M
YoY Change	0.65%	4.47%	3.39%
Goodwill	$1.532B	$1.530B
YoY Change	0.22%	1.63%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$119.4M	$123.2M	$229.1M
YoY Change	-6.88%	-5.99%	4.43%
Total Long-Term Assets	$1.911B	$1.920B	$1.920B
YoY Change	0.54%	2.01%	2.01%
TOTAL ASSETS
Total Short-Term Assets	$408.6M	$428.0M	$428.0M
Total Long-Term Assets	$1.911B	$1.920B	$1.920B
Total Assets	$2.320B	$2.348B	$2.348B
YoY Change	-0.89%	-13.76%	-13.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$35.33M	$31.86M	$31.86M
YoY Change	16.55%	-13.07%	-13.07%
Accrued Expenses	$212.4M	$364.0M	$364.0M
YoY Change	-4.61%	-3.5%	-3.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$14.91M	$14.90M	$14.90M
YoY Change	520.38%	498.31%	498.31%
Total Short-Term Liabilities	$284.2M	$427.0M	$427.0M
YoY Change	5.37%	-0.09%	-0.09%
LONG-TERM LIABILITIES
Long-Term Debt	$742.8M	$636.4M	$636.4M
YoY Change	-7.72%	-36.51%	-36.51%
Other Long-Term Liabilities	$37.65M	$39.41M	$359.3M
YoY Change	-14.19%	-6.9%	1.25%
Total Long-Term Liabilities	$37.65M	$39.41M	$995.6M
YoY Change	-14.19%	-6.9%	-26.63%
TOTAL LIABILITIES
Total Short-Term Liabilities	$284.2M	$427.0M	$427.0M
Total Long-Term Liabilities	$37.65M	$39.41M	$995.6M
Total Liabilities	$1.410B	$1.456B	$1.456B
YoY Change	-3.66%	-20.24%	-20.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$74.86M	-$89.06M
YoY Change	-57.61%	-42.68%
Common Stock	$987.8M	$984.4M
YoY Change	-6.37%	-6.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$909.8M	$891.6M	$891.6M
YoY Change
Total Liabilities & Shareholders Equity	$2.320B	$2.348B	$2.348B
YoY Change	-0.89%	-13.76%	-13.76%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	$14.21M	$29.66M	$66.34M
YoY Change	-167.05%	-37.58%	-49.35%
Depreciation, Depletion And Amortization	$8.953M	$9.136M	$35.64M
YoY Change	2.1%	16.25%	10.85%
Cash From Operating Activities	-$100.9M	$98.69M	$166.9M
YoY Change	3.52%	123.09%	117.55%
INVESTING ACTIVITIES
Capital Expenditures	$6.999M	$9.058M	$29.71M
YoY Change	-197.96%	-385.92%	-192.12%
Acquisitions	$1.667M		$28.17M
YoY Change	-93.51%		-194.11%
Other Investing Activities	-$4.351M	-$2.183M	-$27.25M
YoY Change	4294.95%	-82.42%	30.84%
Cash From Investing Activities	-$11.35M	-$11.24M	-$56.95M
YoY Change	-56.8%	-27.87%	7.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$83.10M
YoY Change			-3994.28%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	108.6M	-86.29M	-487.6M
YoY Change	-142.33%	-10559.27%	-35.86%
NET CHANGE
Cash From Operating Activities	-100.9M	98.69M	166.9M
Cash From Investing Activities	-11.35M	-11.24M	-56.95M
Cash From Financing Activities	108.6M	-86.29M	-487.6M
Net Change In Cash	-3.700M	1.156M	-377.6M
YoY Change	-99.03%	-96.08%	-48.73%
FREE CASH FLOW
Cash From Operating Activities	-$100.9M	$98.69M	$166.9M
Capital Expenditures	$6.999M	$9.058M	$29.71M
Free Cash Flow	-$107.9M	$89.63M	$137.2M
YoY Change	19.46%	89.07%	25.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.mednax.com/20221231#OperatingAndFinanceLeaseRightOfUseAssets
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000893949
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.mednax.com/20221231#OperatingAndFinanceLeaseRightOfUseAssets
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-12111
CY2022	dei	Entity Registrant Name EntityRegistrantName	Pediatrix Medical Group, Inc.
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-3667538
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1301 Concord Terrace
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Sunrise
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33323
CY2022	dei	City Area Code CityAreaCode	954
CY2022	dei	Local Phone Number LocalPhoneNumber	384-0175
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $.01 per share
CY2022	dei	Trading Symbol TradingSymbol	MD
CY2022	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	1242538627
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	83032953
CY2022	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2022	dei	Auditor Firm AuditorFirmId	238
CY2022	dei	Auditor Location AuditorLocation	Hallandale Beach, Florida
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9824000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	387391000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	93239000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	99715000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	296787000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	301775000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	14878000
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	18538000
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0
CY2021Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	14249000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	13261000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	18896000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	427989000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	840564000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	73290000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	70154000
CY2022Q4	us-gaap	Goodwill Goodwill	1532092000
CY2021Q4	us-gaap	Goodwill Goodwill	1505430000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	18491000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	21565000
CY2022Q4	md	Operating And Finance Lease Right Of Use Assets OperatingAndFinanceLeaseRightOfUseAssets	66924000
CY2021Q4	md	Operating And Finance Lease Right Of Use Assets OperatingAndFinanceLeaseRightOfUseAssets	65461000
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	105925000
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	88344000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	123176000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	131028000
CY2022Q4	us-gaap	Assets Assets	2347887000
CY2021Q4	us-gaap	Assets Assets	2722546000
CY2022Q4	md	Accounts Payable And Accrued Liabilities Excluding Accrued Income Taxes Current AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent	374225000
CY2021Q4	md	Accounts Payable And Accrued Liabilities Excluding Accrued Income Taxes Current AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent	394118000
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	14898000
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	2490000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21589000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	19684000
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	16271000
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	11074000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	426983000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	427366000
CY2022Q4	us-gaap	Line Of Credit LineOfCredit	4000000
CY2021Q4	us-gaap	Line Of Credit LineOfCredit	0
CY2022Q4	md	Long Term Debt And Capital Lease Obligations Excluding Long Term Line Of Credit LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit	632381000
CY2021Q4	md	Long Term Debt And Capital Lease Obligations Excluding Long Term Line Of Credit LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit	1002258000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44213000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	41396000
CY2022Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Noncurrent MalpracticeLossContingencyAccrualUndiscountedNoncurrent	275629000
CY2021Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Noncurrent MalpracticeLossContingencyAccrualUndiscountedNoncurrent	271093000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	33638000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	41409000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	39411000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	42332000
CY2022Q4	us-gaap	Liabilities Liabilities	1456255000
CY2021Q4	us-gaap	Liabilities Liabilities	1825854000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	82947000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	82947000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86423000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86423000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	829000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	864000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	983601000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1049696000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3735000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1317000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-89063000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-155390000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	891632000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2722546000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	896487000
CY2022Q4	us-gaap	Minority Interest MinorityInterest	0
CY2021Q4	us-gaap	Minority Interest MinorityInterest	205000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	891632000
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1972021000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1911191000
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1733951000
CY2022	md	Practice Salaries And Benefits PracticeSalariesAndBenefits	1383319000
CY2021	md	Practice Salaries And Benefits PracticeSalariesAndBenefits	1297477000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	896692000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2347887000
CY2020	md	Practice Salaries And Benefits PracticeSalariesAndBenefits	1193940000
CY2022	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	121669000
CY2021	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	100472000
CY2020	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	90690000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	231397000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	263357000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	248947000
CY2022	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	0
CY2021	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	-7280000
CY2020	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	0
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	35636000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	32147000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	28441000
CY2022	us-gaap	Restructuring Charges RestructuringCharges	27312000
CY2021	us-gaap	Restructuring Charges RestructuringCharges	22100000
CY2020	us-gaap	Restructuring Charges RestructuringCharges	73801000
CY2022	us-gaap	Operating Expenses OperatingExpenses	1799333000
CY2021	us-gaap	Operating Expenses OperatingExpenses	1708273000
CY2020	us-gaap	Operating Expenses OperatingExpenses	1635819000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	172688000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	202918000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	98132000
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	3671000
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	13652000
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	17913000
CY2022	us-gaap	Interest Expense InterestExpense	39695000
CY2021	us-gaap	Interest Expense InterestExpense	68722000
CY2020	us-gaap	Interest Expense InterestExpense	110482000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-57016000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-14532000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1722000
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1912000
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1585000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-91318000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-67690000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-90984000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	81370000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	135228000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	7148000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	18806000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	27241000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	16728000
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	62564000
CY2021	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	107987000
CY2020	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-9580000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	3767000
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	22950000
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-786908000
CY2022	us-gaap	Profit Loss ProfitLoss	66331000
CY2021	us-gaap	Profit Loss ProfitLoss	130937000
CY2020	us-gaap	Profit Loss ProfitLoss	-796488000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-27000
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0
CY2022	us-gaap	Net Income Loss NetIncomeLoss	66335000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	130964000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-796488000
CY2022	md	Net Of Tax Unrealized Holding Gain Loss On Investments NetOfTaxUnrealizedHoldingGainLossOnInvestments	1694000
CY2021	md	Net Of Tax Unrealized Holding Gain Loss On Investments NetOfTaxUnrealizedHoldingGainLossOnInvestments	742000
CY2020	md	Net Of Tax Unrealized Holding Gain Loss On Investments NetOfTaxUnrealizedHoldingGainLossOnInvestments	1157000
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-5051000
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-2213000
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	3452000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	61284000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	128751000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-793036000
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.75
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.27
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.11
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.74
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.26
CY2020	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.11
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.04
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.27
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-9.44
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.05
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.27
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-9.44
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.79
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.54
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.55
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.79
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.53
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-9.55
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	83467000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	84832000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	83395000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	84121000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	85828000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	83395000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1498996000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-796488000
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6852000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18118000
CY2020	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	232000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3452000
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7009000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	43009000
CY2020	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	8493000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	747717000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	130964000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-27000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2213000
CY2021	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	4719000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	896692000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	66335000
CY2022	md	Dissolution Of And Net Income Loss Attributable To Noncontrolling Interest DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest	-206000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-5051000
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5396000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16977000
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	88511000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	891632000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	66335000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	130964000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-796488000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	3767000
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	22950000
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-786908000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	35636000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	32147000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	28441000
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1765000
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4335000
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	7163000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-57016000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-14532000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	16127000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	18968000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	39042000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-22771000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-31239000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	36292000
CY2022	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	0
CY2021	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	-7280000
CY2020	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	0
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-144000
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2350000
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	198000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5543000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	72731000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-37937000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-15928000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-41530000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	47956000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-17196000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-9799000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-13916000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	420000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	21326000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	47908000
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	18225000
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-2285000
CY2020	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-6931000
CY2022	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	0
CY2021	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	11000
CY2020	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	0
CY2022	us-gaap	Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve	5600000
CY2021	us-gaap	Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve	1523000
CY2020	us-gaap	Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve	4336000
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-19999000
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-22518000
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	3518000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	182312000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	113760000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	153888000
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-15371000
CY2021	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-37023000
CY2020	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	50732000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	166941000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	76737000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	204620000
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	28167000
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	29930000
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	2225000
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	17346000
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	15052000
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	61845000
CY2022	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	16889000
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	16496000
CY2020	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	33432000
CY2022	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	29708000
CY2021	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	32249000
CY2020	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	28788000
CY2022	us-gaap	Proceeds From Sale Of Buildings ProceedsFromSaleOfBuildings	0
CY2021	us-gaap	Proceeds From Sale Of Buildings ProceedsFromSaleOfBuildings	24728000
CY2020	us-gaap	Proceeds From Sale Of Buildings ProceedsFromSaleOfBuildings	0
CY2022	md	Strategic Investments StrategicInvestments	0
CY2021	md	Strategic Investments StrategicInvestments	-20000000
CY2020	md	Strategic Investments StrategicInvestments	0
CY2022	us-gaap	Proceeds From Sale Of Other Productive Assets ProceedsFromSaleOfOtherProductiveAssets	1378000
CY2021	us-gaap	Proceeds From Sale Of Other Productive Assets ProceedsFromSaleOfOtherProductiveAssets	584000
CY2020	us-gaap	Proceeds From Sale Of Other Productive Assets ProceedsFromSaleOfOtherProductiveAssets	1080000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-56954000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-55423000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-58346000
CY2022	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0
CY2021	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	2350000
CY2020	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	873857000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-56954000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-53073000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	815511000
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	830000000
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0
CY2020	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	527500000
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	826000000
CY2020	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	527500000
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0
CY2022	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	1046880000
CY2021	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	759848000
CY2020	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0
CY2022	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	650000000
CY2021	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0
CY2020	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0
CY2022	md	Payments To Term Loan PaymentsToTermLoan	9375000
CY2021	md	Payments To Term Loan PaymentsToTermLoan	0
CY2020	md	Payments To Term Loan PaymentsToTermLoan	0
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	8621000
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0
CY2020	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	510000
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	189000
CY2020	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0
CY2022	md	Repayments Of Long Term Capital Lease Obligation RepaymentsOfLongTermCapitalLeaseObligation	2916000
CY2021	md	Repayments Of Long Term Capital Lease Obligation RepaymentsOfLongTermCapitalLeaseObligation	2809000
CY2020	md	Repayments Of Long Term Capital Lease Obligation RepaymentsOfLongTermCapitalLeaseObligation	1161000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5396000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6853000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7009000
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	88511000
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	4719000
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	8493000
CY2022	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0
CY2021	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0
CY2020	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	245000
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	9353000
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	596000
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-487554000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-760116000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-2910000
CY2022	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0
CY2021	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0
CY2020	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-1248000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-487554000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-760116000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4158000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-377567000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-736452000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1015973000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	387391000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1123843000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	107870000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9824000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	387391000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1123843000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	116235000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	86537000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	110488000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	26908000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	54728000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-27775000
CY2022	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	282000
CY2021	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	6762000
CY2020	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	12507000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2589000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2300000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2305000
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1. General:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">On July 1, 2022, effective after the close of the market, the Company changed its corporate name from “Mednax, Inc.” to “Pediatrix Medical Group, Inc.” signifying the Company's return to its core focus in caring for women, babies and children. The Company’s common stock continues to trade on the New York Stock Exchange under the ticker symbol “MD.”</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The principal business activity of Pediatrix Medical Group, Inc. (“Pediatrix” or the “Company”) and its subsidiaries is to provide neonatal, maternal-fetal and other pediatric subspecialty physician services. The Company has contracts with affiliated business corporations or professional associations, limited liability companies and partnerships (“affiliated professional contractors”), which are separate legal entities that provide physician services in certain states and Puerto Rico. The Company ceased providing services in Puerto Rico effective December 31, 2022. The Company and its affiliated professional contractors also have contracts with hospitals and other healthcare facilities to provide physician services, which include (i) fee-for-service contracts, whereby hospitals and other customers agree, in exchange for the Company’s services, to authorize the Company and its healthcare professionals to bill and collect the charges for medical services rendered by the Company’s affiliated healthcare professionals, and (ii) administrative fee contracts, whereby the Company is assured a minimum revenue level.</span></p>
CY2021Q4	us-gaap	Investment Owned At Cost InvestmentOwnedAtCost	20000000.0
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Accounting Estimates and Assumptions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions are involved in the calculation of the Company's allowance for contractual adjustments and uncollectibles on accounts receivable, liabilities for self-insured amounts and claims incurred but not reported related to the Company’s professional liability risks and the fair value of goodwill. Actual results could differ from those estimates.</span></p>
CY2022	md	Cash And Cash Equivalents Maturity Description CashAndCashEquivalentsMaturityDescription	90
CY2022	md	Business Combination Contingent Consideration Arrangements Time Period BusinessCombinationContingentConsiderationArrangementsTimePeriod	P5Y
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	93239000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	99715000
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	1548492000
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	1393584000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1251705000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1091809000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	296787000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	301775000
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1972021000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1911191000
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1733951000
CY2022	md	Percentage Of Net Patient Service Revenue By Type Of Payor PercentageOfNetPatientServiceRevenueByTypeOfPayor	1
CY2021	md	Percentage Of Net Patient Service Revenue By Type Of Payor PercentageOfNetPatientServiceRevenueByTypeOfPayor	1
CY2020	md	Percentage Of Net Patient Service Revenue By Type Of Payor PercentageOfNetPatientServiceRevenueByTypeOfPayor	1
CY2022Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	8286000
CY2021Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	8286000
CY2022Q4	us-gaap	Land Land	2032000
CY2021Q4	us-gaap	Land Land	2032000
CY2022Q4	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	235190000
CY2021Q4	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	224524000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	245508000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	234842000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	172218000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	164688000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	73290000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	70154000
CY2022	us-gaap	Depreciation Depreciation	26700000
CY2021	us-gaap	Depreciation Depreciation	21600000
CY2020	us-gaap	Depreciation Depreciation	19300000
CY2022Q4	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	26700000
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles	2300000
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	2200000
CY2021	md	Number Of Physician Group Practices Acquired NumberOfPhysicianGroupPracticesAcquired	9
CY2021	md	Number Of Pediatric Subspecialty Practices Acquired NumberOfPediatricSubspecialtyPracticesAcquired	1
CY2021	md	Number Of Pediatric Cardiology Acquired NumberOfPediatricCardiologyAcquired	1
CY2021	md	Number Of Pediatric Neurology Practices Acquired NumberOfPediatricNeurologyPracticesAcquired	2
CY2021	md	Number Of Maternal Fetal Medicine Practices Acquired NumberOfMaternalFetalMedicinePracticesAcquired	1
CY2021	md	Number Of Obstetrics And Gynecology Practices Acquired NumberOfObstetricsAndGynecologyPracticesAcquired	1
CY2021	md	Number Of Pediatric Intensivist Practice Acquired NumberOfPediatricIntensivistPracticeAcquired	1
CY2021	md	Number Of Neonatology Practices Acquired NumberOfNeonatologyPracticesAcquired	1
CY2022Q4	us-gaap	Goodwill Goodwill	1530000000
CY2021Q4	us-gaap	Goodwill Goodwill	1510000000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	110020000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	91529000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	18491000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	109343000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	87778000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	21565000
CY2022	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	2300000
CY2022	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P13Y
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6400000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8000000.0
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7600000
CY2021Q4	md	Accrued Payroll Taxes And Benefits Current AccruedPayrollTaxesAndBenefitsCurrent	34994000
CY2022Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Current MalpracticeLossContingencyAccrualUndiscountedCurrent	32232000
CY2021Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Current MalpracticeLossContingencyAccrualUndiscountedCurrent	37729000
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	8921000
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	29052000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	68401000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	41724000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	374225000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	5173000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3561000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2095000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1426000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1140000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	31857000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	36645000
CY2022Q4	md	Accrued Salaries And Incentive Compensation Current AccruedSalariesAndIncentiveCompensationCurrent	197831000
CY2021Q4	md	Accrued Salaries And Incentive Compensation Current AccruedSalariesAndIncentiveCompensationCurrent	213974000
CY2022Q4	md	Accrued Payroll Taxes And Benefits Current AccruedPayrollTaxesAndBenefitsCurrent	34983000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	394118000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	55796000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	51283000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21589000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	19684000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44213000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	41396000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.046
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.047
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	22293000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	19907000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	6640000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	5060000
CY2022	md	Operating Leases Other Costs OperatingLeasesOtherCosts	4218000
CY2021	md	Operating Leases Other Costs OperatingLeasesOtherCosts	4235000
CY2022	us-gaap	Lease Cost LeaseCost	33151000
CY2021	us-gaap	Lease Cost LeaseCost	29202000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	37549000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	34054000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	21994000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	19242000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	12162000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	7634000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	4496000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	5175000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	70703000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4901000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	65802000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21589000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44213000
CY2022Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted MalpracticeLossContingencyAccrualUndiscounted	307900000
CY2021Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted MalpracticeLossContingencyAccrualUndiscounted	308800000
CY2022Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	215500000
CY2021Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	211200000
CY2022Q4	md	Accrued Professional Liability AccruedProfessionalLiability	92400000
CY2021Q4	md	Accrued Professional Liability AccruedProfessionalLiability	97600000
CY2022Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Current MalpracticeLossContingencyAccrualUndiscountedCurrent	32200000
CY2022Q4	us-gaap	Insurance Settlements Receivable InsuranceSettlementsReceivable	54700000
CY2021Q4	md	Malpractice Loss Contingency Accrual Undiscounted Excluding Retained Professional Liabilities Related To Anesthesiology And Radiology Operations MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations	190127000
CY2020Q4	md	Malpractice Loss Contingency Accrual Undiscounted Excluding Retained Professional Liabilities Related To Anesthesiology And Radiology Operations MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations	174803000
CY2019Q4	md	Malpractice Loss Contingency Accrual Undiscounted Excluding Retained Professional Liabilities Related To Anesthesiology And Radiology Operations MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations	151397000
CY2022	md	Accrued Professional Liabilities Assumed Through Acquisition AccruedProfessionalLiabilitiesAssumedThroughAcquisition	-2692000
CY2021	md	Accrued Professional Liabilities Assumed Through Acquisition AccruedProfessionalLiabilitiesAssumedThroughAcquisition	-2299000
CY2020	md	Accrued Professional Liabilities Assumed Through Acquisition AccruedProfessionalLiabilitiesAssumedThroughAcquisition	3922000
CY2022	md	Provision Adjustment For Losses Related To Current Year ProvisionAdjustmentForLossesRelatedToCurrentYear	53180000
CY2021	md	Provision Adjustment For Losses Related To Current Year ProvisionAdjustmentForLossesRelatedToCurrentYear	56016000
CY2020	md	Provision Adjustment For Losses Related To Current Year ProvisionAdjustmentForLossesRelatedToCurrentYear	45674000
CY2022	md	Provision Adjustment For Losses Related To Prior Year ProvisionAdjustmentForLossesRelatedToPriorYear	-4056000
CY2021	md	Provision Adjustment For Losses Related To Prior Year ProvisionAdjustmentForLossesRelatedToPriorYear	-14231000
CY2020	md	Provision Adjustment For Losses Related To Prior Year ProvisionAdjustmentForLossesRelatedToPriorYear	-1551000
CY2022	md	Malpractice Loss Contingency Provision For Losses MalpracticeLossContingencyProvisionForLosses	49124000
CY2021	md	Malpractice Loss Contingency Provision For Losses MalpracticeLossContingencyProvisionForLosses	41785000
CY2020	md	Malpractice Loss Contingency Provision For Losses MalpracticeLossContingencyProvisionForLosses	44123000
CY2022	us-gaap	Malpractice Loss Contingency Claims Incurred In Period MalpracticeLossContingencyClaimsIncurredInPeriod	73000
CY2021	us-gaap	Malpractice Loss Contingency Claims Incurred In Period MalpracticeLossContingencyClaimsIncurredInPeriod	59000
CY2020	us-gaap	Malpractice Loss Contingency Claims Incurred In Period MalpracticeLossContingencyClaimsIncurredInPeriod	59000
CY2022	us-gaap	Malpractice Loss Contingency Claims Incurred In Prior Periods MalpracticeLossContingencyClaimsIncurredInPriorPeriods	36925000
CY2021	us-gaap	Malpractice Loss Contingency Claims Incurred In Prior Periods MalpracticeLossContingencyClaimsIncurredInPriorPeriods	24103000
CY2020	us-gaap	Malpractice Loss Contingency Claims Incurred In Prior Periods MalpracticeLossContingencyClaimsIncurredInPriorPeriods	24580000
CY2022	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	36998000
CY2021	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	24162000
CY2020	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	24639000
CY2022Q4	md	Malpractice Loss Contingency Accrual Undiscounted Excluding Retained Professional Liabilities Related To Anesthesiology And Radiology Operations MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations	199561000
CY2021Q4	md	Malpractice Loss Contingency Accrual Undiscounted Excluding Retained Professional Liabilities Related To Anesthesiology And Radiology Operations MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations	190127000
CY2020Q4	md	Malpractice Loss Contingency Accrual Undiscounted Excluding Retained Professional Liabilities Related To Anesthesiology And Radiology Operations MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations	174803000
CY2022Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.05375
CY2022	us-gaap	Debt Instrument Frequency Of Periodic Payment DebtInstrumentFrequencyOfPeriodicPayment	payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022
CY2022	us-gaap	Debt Instrument Description DebtInstrumentDescription	Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions
CY2022Q4	md	Purchase Price PurchasePrice	1.01
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	637200000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	989700000
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	644625000
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	7385000
CY2022Q4	md	Long Term Debt Net LongTermDebtNet	637240000
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1000000000
CY2021Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	10340000
CY2021Q4	md	Long Term Debt Net LongTermDebtNet	989660000
CY2022Q4	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	446000000.0
CY2022	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	February 2022
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	11128000
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	14178000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2398000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2490000
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	8730000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	11688000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	38877000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	41592000
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-16610000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-19679000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-20373000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	28719000
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	19198000
CY2021	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	21219000
CY2020	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	12109000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2700000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	16888000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-2954000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3092000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-10866000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	7573000
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-392000
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	6022000
CY2020	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	4619000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	18806000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	27241000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	16728000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.231
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.201
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	2.340
CY2021	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	10800000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0153
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0472
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.2434
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0148
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0342
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.6044
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0135
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0077
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.9861
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0328
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0108
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0422
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0172
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0026
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2367
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0069
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0046
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0171
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0797
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2311
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2014
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	2.3399
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	152526000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	135280000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	66969000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	55549000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3694000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3303000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	28773000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	29045000
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	422793000
CY2021Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	428805000
CY2022Q4	md	Deferred Tax Assets Operating Lease Assets DeferredTaxAssetsOperatingLeaseAssets	19096000
CY2021Q4	md	Deferred Tax Assets Operating Lease Assets DeferredTaxAssetsOperatingLeaseAssets	18960000
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2481000
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1967000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	256000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	686000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	696588000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	673595000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	429260000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	441529000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	267328000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	232066000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	176398000
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	168505000
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	16510000
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	16439000
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	2133000
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	187000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	195041000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	185131000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	72287000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	46935000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	72300000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	46900000
CY2022	md	Increase Decrease In Deferred Tax Assets IncreaseDecreaseInDeferredTaxAssets	25400000
CY2022	md	Increase Decrease In Uncollectible Account Related To Deferred Tax Assets IncreaseDecreaseInUncollectibleAccountRelatedToDeferredTaxAssets	17200000
CY2022	md	Increase Decrease In Valuation Allowance IncreaseDecreaseInValuationAllowance	12200000
CY2022	us-gaap	Increase Decrease In Future Policy Benefit Reserves IncreaseDecreaseInFuturePolicyBenefitReserves	11400000
CY2022	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	7900000
CY2022	md	Income Tax Expense For Excess Tax Deficiencies IncomeTaxExpenseForExcessTaxDeficiencies	1100000
CY2021	md	Income Tax Expense For Excess Tax Deficiencies IncomeTaxExpenseForExcessTaxDeficiencies	1000000.0
CY2020	md	Income Tax Expense For Excess Tax Deficiencies IncomeTaxExpenseForExcessTaxDeficiencies	7100000
CY2022Q4	md	Capital Loss Carryforwards CapitalLossCarryforwards	1710000000
CY2021	md	Capital Losses Incurred CapitalLossesIncurred	25900000
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	46700000
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	61700000
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	35400000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	26400000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	20300000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2800000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4900000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6200000
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2800000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4928000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6168000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7409000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	379000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1041000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	800000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	900000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	100000
CY2020	md	Unrecognized Tax Benefits Decrease Resulting From Divestitures UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures	-300000
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	3269000
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	2140000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2838000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4928000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6168000
CY2022	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	500000
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	300000
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	400000
CY2020	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	500000
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	200000
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	800000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	83467000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	84832000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	83395000
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	654000
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	996000
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	84121000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	85828000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	83395000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	406000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1034000
CY2020	md	Incremental Shares In Continuing Operation IncrementalSharesInContinuingOperation	600000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14400000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19000000.0
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21100000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1143806
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	25.68
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	841196
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	22.64
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	59555
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	24.46
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	730050
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	26.14
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1195397
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	23.32
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	19100000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	25100000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	59300000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	22.64
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	25.17
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	23.54
CY2021Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	1091310000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	887731
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.91
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2020Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	791842000
CY2019Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	746388000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	887731
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.91
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y10M17D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	887731
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	16.91
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P0Y10M17D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0
CY2022	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0
CY2018Q3	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	500000000.0
CY2018Q3	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	5500000
CY2022Q4	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	4500000
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	88500000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	22600000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	21000000.0
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	19900000
CY2022	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	5921519000
CY2020	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	4776447000
CY2021	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	5436786000
CY2022	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	-5761124000
CY2021	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	-5137318000
CY2020	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	-4730993000
CY2022Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	1251705000
CY2021Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	1091310000
CY2020Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	791842000

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
0000950170-23-003127-index-headers.html	Edgar Link	pending
0000950170-23-003127-index.html	Edgar Link	pending
0000950170-23-003127.txt	Edgar Link	pending
0000950170-23-003127-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img258448819_0.jpg	Edgar Link	pending
md-20221231.htm	Edgar Link	pending
md-20221231.xsd	Edgar Link	pending
md-ex21_1.htm	Edgar Link	pending
md-ex23_1.htm	Edgar Link	pending
md-ex31_1.htm	Edgar Link	pending
md-ex31_2.htm	Edgar Link	pending
md-ex32.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
md-20221231_cal.xml	Edgar Link	unprocessable
md-20221231_def.xml	Edgar Link	unprocessable
md-20221231_lab.xml	Edgar Link	unprocessable
md-20221231_pre.xml	Edgar Link	unprocessable
md-20221231_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MD
Pediatrix Medical Group, Inc. Stock $md

2023 Q1 Form 10-K Financial Statement

#000095017023003127 Filed on February 17, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MD Pediatrix Medical Group, Inc. Stock $md

2023 Q1 Form 10-K Financial Statement

#000095017023003127 Filed on February 17, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MD
Pediatrix Medical Group, Inc. Stock $md